2017年获暨南大学博士学位，2017-2022年在中山大学从事博士后研究。目前，任广州健康研究院副研究员，硕士研究生导师，中国科学院青年创新促进会会员。主要从事基于核酸纳米药物的肿瘤免疫治疗研究，累计已发表论文28篇，H指数19。其中，以第一（含共第一）或通讯作者发表SCI论文12篇，累计被引1200余次。中国科学院B类先导专项（国家科技重大任务）课题负责人，国家重点研发计划子任务负责人，主持国家自然科学基金青年基金、广东省自然科学基金、中国博士后科学基金、广州市科技计划项目。获授权发明专利2项。受邀担任《Cancer Drug Resistance》杂志青年编委、中国药理学会学术会员、广东省研究型医院学会会员。

基于核酸纳米药物的肿瘤免疫治疗研究

代表性论文(#Join first co-author，*corresponding author）：

[1] Li Y#, Bai L#, Yu H, Cai D, Wang X, Huang B, Peng S, Huang M, Cao G, Kaz AM, Grady WM, Wang J, and Luo Y*. Epigenetic inactivation of α-internexin accelerates microtubule polymerization in colorectal cancer. Cancer Res. 2020; 80(23):5203-15.

[2] Zhu M#, Bai L#, Liu X#, Peng S, Xie Y, Bai H, Yu H, Wang X, Lin J, Wu L, Huang M, Li Y*, Luo Y*. Silence of dependence receptor CSF1R activates tumor-associated macrophages in colorectal cancer. J ImmunoTher Cancer. 2022; 10:e005610.

[3] Li Y#, Lei Y#, Yao N, Wang C, Hu N, Ye W, Zhang D* and Chen Z*. Autophagy and multidrug resistance in cancer. Cancer Commun. 2017; 36(1): 52.

[4] Fang C #, Liu Z #, Bai L #, Ma L, Xiong W, Sun L, Wu L, Ni J, Zhang W, Zhu Y, Luo Y *, Li Y*, Zhang C*. A new sodium ionophore Polydecalinmycin with octalin ring improves skin wound healing in diabetes. Nature Communications. (Under review, NCOMMS-25-70185)

[5] Bai L#, Wu L#, Zhang C, Liu Z, Ma L, Ni J, He D, Zhu M, Peng S, Liu X, Yu H, Lei Y, Luo Y, Zhang Y, Wang X*, Wei G*, Li Y*. Replenishment of mitochondrial Na+ and H+ by ionophores potentiates cutaneous wound healing in diabetes. Materials Today Bio. 2024; 26 (2024) 101056.

[6] Yao N#, Li Y#, Lei Y#, Hu N, Chen W, Yao Z, Yu M, Liu J, Ye W* and Zhang D*. A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2016; 35(1): 192.

[7] Peng S#, Li Y#, Huang M, Tang G, Xie Y, Chen D, Hu Y, Yu T, Cai J, Yuan Z, Wang H, Wang H, Luo Y*, Liu X*. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. Int J Biol Sci. 2022; 18(5):1912-1932

[8] Lei Y#, Zhang E#, Bai L*, Li Y*. Autophagy in cancer immunotherapy. Cells. 2022. 11 (19) :2996

[9] Liu D#, Li Y#, Yang D, Wang C, Xu J, Yao N, Zhang X, Chen Z, Ye W* and Zhang DM*. Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. Int J Oncol. 2015; 46(5): 2029-38.

[10] Liu D#, Li Y#, Yao N,Xu J, Chen Z, Yiu A, Zhang C, Ye W*, Zhang D*. Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. Eur J Pharmacol. 2014; 733C: 34-44.

代表性专利：

1. 一类化合物促皮肤损伤修复的用途. 中国发明专利. ZL202010566166.5, 第一发明人

2. 化合物促皮肤损伤修复的用途. 中国发明专利. ZL202111044412.1, 第一发明人